Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
- Conditions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT02186249
- Locations
- 🇺🇸
Medstar Health Research Institute, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 158
- Registration Number
- NCT02174172
- Locations
- 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- Duke University
- Target Recruit Count
- 4
- Registration Number
- NCT02115243
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Grupo Español Multidisciplinar de Melanoma
- Target Recruit Count
- 58
- Registration Number
- NCT02115139
- Locations
- 🇪🇸
H.U. Virgen Macarena, Sevilla, Spain
🇪🇸Clínica Universidad de Navarra, Pamplona, Spain
🇪🇸H. Clinic de Barcelona, Barcelona, Spain
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT02113657
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02097732
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 4
- Registration Number
- NCT02094391
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2020-06-05
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 132
- Registration Number
- NCT02073123
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸Penn State Hershey Cancer Institue, Hershey, Pennsylvania, United States
🇺🇸Augusta University, Augusta, Georgia, United States
A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.
- Conditions
- Interventions
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT02068196
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
🇳🇴Oslo University Hospital, Oslo, Norway
🇳🇴Nordland Hospital Bodø, Bodø, Norway
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 385
- Registration Number
- NCT02060188
- Locations
- 🇺🇸
Local Institution - 0028, Gilbert, Arizona, United States
🇺🇸Local Institution - 0004, Los Angeles, California, United States
🇺🇸Local Institution - 0036, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.